U.S. Markets close in 5 hrs 12 mins
S&P 500
3,373.74+13.27(+0.39%)Nasdaq
10,925.15-43.20(-0.39%)Russell 2000
1,596.12+11.45(+0.72%)
AVEO Pharmaceuticals, Inc. (AVEO)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
4.5554-0.0846 (-1.82%)
As of 10:47AM EDT. Market open.
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 4.6400 |
| Open | 4.6500 |
| Bid | 4.5400 x 1000 |
| Ask | 4.5600 x 900 |
| Day's Range | 4.5100 - 4.6550 |
| 52 Week Range | 2.2300 - 11.2000 |
| Volume | 46,050 |
| Avg. Volume | 755,445 |
| Market Cap | 117.555M |
| Beta (5Y Monthly) | 1.52 |
| PE Ratio (TTM) | 162.69 |
| EPS (TTM) | 0.0280 |
| Earnings Date | Apr 30, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.67 |
- Zacks
AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates
AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.
- Zacks
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of 17.65% and -49.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
AVEO Oncology Announces Restructuring of Existing Term Loan with Closing of New Tranched, $35 Million Debt Facility
AVEO Oncology (Nasdaq: AVEO) today announced the closing of a tranched, $35 million debt facility with Hercules Capital, Inc. (NYSE: HTGC) and its affiliates. The new facility has a maturity of 36 months, extendable up to 48 months, and an interest-only period of 12 months, extendable up to 30 months upon the achievement of performance milestones related to the approval and commercialization of tivozanib.
© 2020 Verizon Media. All rights reserved.
